EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design

Simone Birocchi, Matteo Rocchetti, Alessandro Minardi, Gian Marco Podda, Alessandro Squizzato iD, Marco Cattaneo

Thrombosis and Haemostasis · 01.05.2024 · 124 (05) · 482-496

DOI: 10.1055/a-2149-4344 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2024. Verfasst von Simone Birocchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Divisione di Medicina Generale II, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Randomized Controlled Trials as Topic, Purinergic P2Y Receptor Antagonists, Platelet Function Tests. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The value of guided therapy (GT) with anti-P2Y12 drugs in percutaneous coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized controlled trials (RCTs) with heterogeneous designs, comparing either genotype-GT or platelet function test (PFT)-GT with unguided therapy. Some meta-analysis also included RCTs that did not explore GT, but included the effects of switching patients with high on-treatment platelet reactivity (HTPR) to alternative therapies (HTPR-Therapy). We performed three distinct systematic reviews/meta-analyses, each exploring only RCTs with homogeneous design.

Methods

MEDLINE, Embase, and Central databases were searched for RCTs testing genotype-GT, PFT-GT, or HTPR-Therapy in PCI-treated patients, through October 1, 2022. Two reviewers extracted the data. Risk ratios (RRs) (95% confidence intervals) were calculated. Primary outcomes were major bleedings (MBs) and major adverse cardiovascular events (MACE).

Results

In seven genotype-GT RCTs, RRs were: MB, 1.06 (0.73–1.54; p = 0.76); MACE, 0.65 (0.47–0.91; p = 0.01), but significant risk reduction was observed in RCTs performed in China (0.30, 0.16–0.54; p < 0.0001) and not elsewhere (0.75, 0.48–1.18; p = 0.21). In six PFT-GT RCTs, RRs were: MB, 0.91 (0.64–1.28, p = 0.58); MACE, 0.82 (0.56–1.19; p = 0.30): 0.62 (0.42–0.93; p = 0.02) in China, 1.08 (0.82–1.41; p = 0.53) elsewhere. In eight HTPR-Therapy RCTs, RRs were: MB, 0.71 (0.41–1.23; p = 0.22); MACE, 0.57 (0.44–0.75; p < 0.0001): 0.56 (0.43–0.74, p < 0.0001) in China, 0.58 (0.27–1.23, p = 0.16) elsewhere.

Conclusion

No GT strategy affected MB. Overall, genotype-GT but not PFT-GT reduced MACE. However, genotype-GT and PFT-GT reduced MACE in China, but not elsewhere. PFT-GT performed poorly compared to HTPR-Therapy, likely due to inaccurate identification of HTPR patients by PFT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionRandomized Controlled Trials as TopicPurinergic P2Y Receptor AntagonistsPlatelet Function TestsPlatelet Aggregation InhibitorsHumansHemorrhageBlood PlateletsTreatment OutcomeReceptors, Purinergic P2Y12Coronary Artery DiseaseGenotype

Substanzen

Purinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsReceptors, Purinergic P2Y12

Autor:innen und Institutionen

  • Divisione di Medicina Generale II, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy.
  • Divisione di Cardiologia, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy.
  • Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy.
  • Fondazione Arianna Anticoagulazione, Bologna, Italy.

ORCID-Profile: Alessandro Squizzato

Zitieren

APA

Birocchi, S., Rocchetti, M., Minardi, A., Podda, G. M., Squizzato, A., & Cattaneo, M. (2024). Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design. Thrombosis and Haemostasis, 124(05), 482-496. https://doi.org/10.1055/a-2149-4344

Vancouver

Birocchi S, Rocchetti M, Minardi A, Podda GM, Squizzato A, Cattaneo M. Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design. Thrombosis and Haemostasis. 2024;124(05):482-496. doi:10.1055/a-2149-4344

BibTeX
@article{Birocchi2024,
  author = {Birocchi, Simone and Rocchetti, Matteo and Minardi, Alessandro and Podda, Gian Marco and Squizzato, Alessandro and Cattaneo, Marco},
  title = {Guided Anti-P2Y12 Therapy in Patients Undergoing PCI: Three Systematic Reviews with Meta-analyses of Randomized Controlled Trials with Homogeneous Design},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {05},
  pages = {482--496},
  doi = {10.1055/a-2149-4344}
}
Kostenlos starten →